Jakafi 5 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FKJG9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,397
Award facts
- Contract value 100% obligated
- $12,396.58 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $12,396.58 to DMS Pharmaceutical Group Inc. for 60 tablets of Jakafi 5 mg, with an ultimate completion date of November 28, 2025. This delivery order was issued without a set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as a critical supplier within the Department of Defense pharmaceutical supply chain and has maintained registration in the System for Award Management since July 2001.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036. The PPV-G GEN V contract, part of a broader $30.3 billion acquisition strategy, authorizes DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities worldwide. Jakafi (ruxolitinib) is a specialty pharmaceutical used in hematologic and immunologic conditions, consistent with DMS Pharmaceutical Group's demonstrated capability to supply branded and generic prescription medications, biologics, and specialized therapeutic agents across multiple product categories.
Quick answers
Who was awarded contract SPE2DR26FKJG9?
SPE2DR26FKJG9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 26, 2025.
How much is contract SPE2DR26FKJG9 worth?
The government has obligated $12,397 on SPE2DR26FKJG9.
Is contract SPE2DR26FKJG9 an order under another contract?
Yes. SPE2DR26FKJG9 is a delivery order under SPE2DR25D9105, an indefinite delivery contract.
Was contract SPE2DR26FKJG9 competed?
The extent of competition for SPE2DR26FKJG9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award